ADC Payload Platform Akari is developing antibody drug conjugates using the PH1 payload platform to target CEACAM5, a tumor antigen expressed across multiple solid tumors. This opens opportunities for licensing, co-development, or collaboration with partners seeking differentiated RNA splice modulating payloads in oncology.

Manufacturing Partnerships The company has an active development and manufacturing partnership with WuXi XDC for its ADC programs, indicating a readiness to engage external CDMOs and scale-up capabilities for multi-program pipelines.

Leadership Momentum Recent leadership actions and a new Scientific Advisory Board member from Dana-Farber signal a ramp in R&D collaboration and access to leading academic resources, creating avenues for joint research deals and data-driven partnering.

Conference Outreach Akari maintains visible engagement at major oncology conferences such as ASCO and AACR, presenting themes from recent meetings—an opportunity to schedule early meetings with potential partners and discuss pipeline priorities.

Partnership Appetite As a small, early-stage biotech with modest revenue, Akari appears poised to pursue licensing, co-development, or milestone-based partnerships to advance ADC programs rather than standalone commercialization.